Ibrexafungerp Citrate Patent Expiration
Ibrexafungerp Citrate is Used for preventing and treating recurrent and acute vulvovaginal candidiasis in adult and post-menarchal pediatric females. It was first introduced by Scynexis Inc
Ibrexafungerp Citrate Patents
Given below is the list of patents protecting Ibrexafungerp Citrate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Brexafemme | US11534433 | Antifungal agents with enhanced activity in acidic pH | Jun 10, 2039 | Scynexis |
| Brexafemme | US10174074 | Salts and polymorphs of SCY-078 | Jan 19, 2035 | Scynexis |
| Brexafemme | US10370406 | Salts and polymorphs of SCY-078 | Jan 19, 2035 | Scynexis |
| Brexafemme | US10927142 | Salts and polymorphs of SCY-078 | Jan 19, 2035 | Scynexis |
| Brexafemme | US8188085 | Antifungal agents | Aug 28, 2030 | Scynexis |
Ibrexafungerp Citrate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List